Corrigendum to “Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling” (Molecular Oncology (2015) 9(1) (44–57) (S1574789114001689) (10.1016/j.molonc.2014.07.013));Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 44-57

  Hu, Shuai ^a,b   Li, Lei ^b   Yeh, Shuyuan ^b   Cui, Yun ^a   Li, Xin ^a   Chang, Hong Chiang ^b   Jin, Jie ^a   Chang, Chawnshang ^b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Androgen receptor; Prostate cancer; T cells; Tumor metastasis; Tumor microenvironment

Indexed keywords

ANDROGEN RECEPTOR; CXCL9 CHEMOKINE; ENZALUTAMIDE; GELATINASE B; MICRORNA; MIRNA 541; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; MIRN541 MICRORNA, HUMAN; MMP9 PROTEIN, HUMAN; RNA; TUMOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURGERY; CD4+ T LYMPHOCYTE; CELL INVASION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MALE; METASTASIS; MODULATION; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR INVASION; AGED; ANIMAL; CELL MOTION; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 84920610374     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.10.005     Document Type: Erratum

References (46)

1. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
2. Bromwich E.J., McArdle P.A., Canna K., McMillan D.C., McNicol A.M., Brown M., Aitchison M. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br. J. Cancer 2003, 89:1906-1908.
3. Chang C., Lee S.O., Yeh S., Chang T.M. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 2013, 33:3225-3234.
4. Chang C.S., Kokontis J., Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988, 240:324-326.
5. Ebelt K., Babaryka G., Figel A.M., Pohla H., Buchner A., Stief C.G., Eisenmenger W., Kirchner T., Schendel D.J., Noessner E. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008, 68:1-10.
6. Ebelt K., Babaryka G., Frankenberger B., Stief C.G., Eisenmenger W., Kirchner T., Schendel D.J., Noessner E. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur. J. Cancer 2009, 45:1664-1672.
7. Fang L.Y., Izumi K., Lai K.P., Liang L., Li L., Miyamoto H., Lin W.J., Chang C. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res. 2013, 73:5633-5646.
8. Feng S., Dakhova O., Creighton C.J., Ittmann M. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013, 73:2551-2562.
9. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
10. Gannon P.O., Poisson A.O., Delvoye N., Lapointe R., Mes-Masson A.M., Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J.Immunol. Methods 2009, 348:9-17.
11. Hara T., Miyazaki H., Lee A., Tran C.P., Reiter R.E. Androgen receptor and invasion in prostate cancer. Cancer Res. 2008, 68:1128-1135.
12. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
13. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25:276-308.
14. Izumi K., Fang L.Y., Mizokami A., Namiki M., Li L., Lin W.J., Chang C. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol. Med. 2013, 5:1383-1401.
15. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
16. Koch A.E. Chemokines and their receptors in rheumatoid arthritis: future targets?. Arthritis Rheum. 2005, 52:710-721.
17. Lai K.P., Yamashita S., Huang C.K., Yeh S., Chang C. Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines. EMBO Mol. Med. 2012, 4:791-807.
18. Lin T.H., Izumi K., Lee S.O., Lin W.J., Yeh S., Chang C. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013, 4:e764.
19. Lin T.H., Lee S.O., Niu Y., Xu D., Liang L., Li L., Yeh S.D., Fujimoto N., Yeh S., Chang C. Differential androgen deprivation therapies with anti-androgens Casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. J.Biol. Chem. 2013, 288:19359-19369.
20. Lin Y., Wang F. FGF signalling in prostate development, tissue homoeostasis and tumorigenesis. Biosci. Rep. 2010, 30:285-291.
21. Luo J., Ok Lee S., Liang L., Huang C.K., Li L., Wen S., Chang C. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 2013, 33:2768-2778.
22. Ma W.L., Hsu C.L., Yeh C.C., Wu M.H., Huang C.K., Jeng L.B., Hung Y.C., Lin T.Y., Yeh S., Chang C. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 2012, 56:176-185.
23. Maitland N.J., Collins A.T. Prostate cancer stem cells: a new target for therapy. J.Clin. Oncol. 2008, 26:2862-2870.
24. McArdle P.A., Canna K., McMillan D.C., McNicol A.M., Campbell R., Underwood M.A. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br. J. Cancer 2004, 91:541-543.
25. Mercader M., Bodner B.K., Moser M.T., Kwon P.S., Park E.S., Manecke R.G., Ellis T.M., Wojcik E.M., Yang D., Flanigan R.C., Waters W.B., Kast W.M., Kwon E.D. Tcell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14565-14570.
26. Niu Y., Altuwaijri S., Lai K.P., Wu C.T., Ricke W.A., Messing E.M., Yao J., Yeh S., Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12182-12187.
27. Niu Y., Altuwaijri S., Yeh S., Lai K.P., Yu S., Chuang K.H., Huang S.P., Lardy H., Chang C. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12188-12193.
28. Niu Y., Chang T.M., Yeh S., Ma W.L., Wang Y.Z., Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010, 29:3593-3604.
29. Oldham K.A., Parsonage G., Bhatt R.I., Wallace D.M., Deshmukh N., Chaudhri S., Adams D.H., Lee S.P. Tlymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur. Urol 2012, 61:385-394.
30. Omabe M., Ezeani M. Infection, inflammation and prostate carcinogenesis. Infection, genetics and evolution. J.Mol. Epidemiol. Evol. Genet. Infect. Dis. 2011, 11:1195-1198.
31. Ostling P., Leivonen S.K., Aakula A., Kohonen P., Makela R., Hagman Z., Edsjo A., Kangaspeska S., Edgren H., Nicorici D., Bjartell A., Ceder Y., Perala M., Kallioniemi O. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 2011, 71:1956-1967.
32. Reebye V., Frilling A., Habib N.A., Mintz P.J. Intracellular adaptor molecules and AR signalling in the tumour microenvironment. Cell Signal 2011, 23:1017-1021.
33. Sanchez C., Chan R., Bajgain P., Rambally S., Palapattu G., Mims M., Rooney C.M., Leen A.M., Brenner M.K., Vera J.F. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013, 16:123-131. S121.
34. Shore N.D., Mantz C.A., Dosoretz D.E., Fernandez E., Myslicki F.A., McCoy C., Finkelstein S.E., Fishman M.N. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Cancer control. J.Moffitt Cancer Cent. 2013, 20:7-16.
35. Steiner G.E., Djavan B., Kramer G., Handisurya A., Newman M., Lee C., Marberger M. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev. Urol. 2002, 4:171-177.
36. Sun Y., Wang B.E., Leong K.G., Yue P., Li L., Jhunjhunwala S., Chen D., Seo K., Modrusan Z., Gao W.Q., Settleman J., Johnson L. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res. 2012, 72:527-536.
37. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J.Q., Hoffman R.M., Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470:548-553.
38. Teishima J., Shoji K., Hayashi T., Miyamoto K., Ohara S., Matsubara A. Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence. Prostate Cancer Prostatic Dis. 2012, 15:8-14.
39. Tu S.M., Lin S.H. Prostate cancer stem cells. Clin. Genitourin Cancer 2012, 10:69-76.
40. Valta M.P., Tuomela J., Bjartell A., Valve E., Vaananen H.K., Harkonen P. FGF-8 is involved in bone metastasis of prostate cancer. Int. J. Cancer 2008, 123:22-31.
41. Vendramini-Costa D.B., Carvalho J.E. Molecular link mechanisms between inflammation and cancer. Curr. Pharm. Des. 2012, 18:3831-3852.
42. Wang X., Lee S.O., Xia S., Jiang Q., Luo J., Li L., Yeh S., Chang C. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-beta→MMP-9 signals. Mol. Cancer Ther. 2013, 12:1026-1037.
43. Wen S., Niu Y., Lee S.O., Chang C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat. Rev. 2013, 40:31-40.
44. Wesche J., Haglund K., Haugsten E.M. Fibroblast growth factors and their receptors in cancer. Biochem. J. 2011, 437:199-213.
45. Yates C. Prostate tumor cell plasticity: a consequence of the microenvironment. Adv. Exp. Med. Biol. 2011, 720:81-90.
46. Zhang J., Liu L.H., Zhou Y., Li Y.P., Shao Z.H., Wu Y.J., Li M.J., Fan Y.Y., Shi H.J. Effects of miR-541 on neurite outgrowth during neuronal differentiation. Cell Biochem. Funct. 2011, 29:279-286.